| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:CM-414
CAS:1624792-70-6
Purity:98% Package:5 mg
|
|
| | cis CM-414 Basic information |
| Product Name: | cis CM-414 | | Synonyms: | cis CM-414;Cyclobutanecarboxamide, 3-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]methyl]-N-hydroxy-, cis- | | CAS: | 1624792-70-6 | | MF: | C23H29N5O4 | | MW: | 439.51 | | EINECS: | | | Product Categories: | | | Mol File: | 1624792-70-6.mol |  |
| | cis CM-414 Chemical Properties |
| density | 1.40±0.1 g/cm3(Predicted) | | pka | 9.46±0.23(Predicted) |
| | cis CM-414 Usage And Synthesis |
| Description | CM-414 is a dual inhibitor of PDE5 and HDACs for the Treatment of Alzheimer’s Disease (IC50 values of 60 nM, 310 nM, 490 nM, 322 nM, and 91 nM against PDE5, HDAC1, HDAC2, HDAC3, and HDAC6, respectively). Chronic treatment of Tg2576 mice with CM-414 diminished brain Aβ and tau phosphorylation (pTau) levels, increased the inactive form of GSK3β, reverted the decrease in dendritic spine density on hippocampal neurons, and reversed their cognitive deficits, at least in part by inducing the expression of genes related to synaptic transmission. Thus, CM-414 may serve as the starting point to discover balanced dual inhibitors with an optimal efficacy and safety profile for clinical testing on AD patients. |
| | cis CM-414 Preparation Products And Raw materials |
|